From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

BioThreat Therapeutics Development to Relieve Bottlenecks

by Global Biodefense Staff
July 10, 2014
Thermal Burn Injury Therapeutics Development

Credit: Shutterstock

The NIAID Division of Microbiology and Infectious Diseases (DMID) has issued a new Broad Agency Announcement (BAA) to support the advancement of promising lead therapeutics to the clinical drug candidate stage for the treatment of emerging infectious and biodefense diseases.

Only candidate products against NIAID Category A, B and C Priority Pathogens are eligible under this solicitation.

Activities supported under this BAA include medicinal chemistry and preclinical in vitro and in vivo testing of a lead compound series in order to produce profiles of their efficacy, synthetic feasibility, stability, and toxicity, which will be used to identify a novel small molecule drug candidate for future clinical development. Of particular interest are broad-spectrum antivirals, and broad-spectrum anti-bacterials.

For the purposes of this BAA, the ideal lead compound for development is defined as a small molecule with demonstrated activity in appropriate in vitro assays or in vivo models against one or more selected bacterial or viral pathogens. A lead compound is more advanced in development than hit compounds and lead candidates. Hit compounds are potent modulators that are identified via in vitro or in vivo screening. Lead candidates are selected among the hit compounds for further evaluation.

Contracts awarded under this BAA will support:

  • Chemical synthesis of analogs to develop structure-activity relationship profiles
  • Chemical optimization of core molecular scaffolds to improve physiochemical properties to produce more drug-like molecules
  • Synthetic route-scouting towards process development
  • Formulation studies to optimize dosing, pharmacodynamics, product stability and other drug properties
  • In vitro and non-GLP in vivo testing for toxicity, activity, ADME (absorption, distribution, metabolism, and excretion) properties
  • Preclinical non-GLP efficacy testing for biodefense and emerging infectious diseases

Screening of compound libraries or compound series for hit identification; development of animal models; and development of devices, prophylactic products or diagnostics will not be considered under this funding opportunity.

Lead compounds with broad spectrum activity are encouraged. Broad spectrum activity is defined as a characteristic that enables a particular product to mitigate biological threats across a range or class of agents. There are a number of traditional threats for which effective treatments are either non-existent, of limited usefulness, or vulnerable to both naturally emerging and intentionally engineered antibacterial and antiviral resistance.

A limited number of anti-infectives with broad spectrum activity directed at common, invariable, and essential components of different classes of microbes could potentially be effective against both traditional and non-traditional threats. This approach would allow a small number of drugs to replace dozens of pathogen-specific drugs for use in a biothreat emergency.

Broad spectrum therapeutics supported under this BAA are specified as the following:

Broad spectrum anti-bacterial: Therapeutic with activity against more than one of the NIAID Category A, B and C bacterial threat agent AND including activity against at least one of the following bacterial pathogens: Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, and Rickettsia prowazeki.

Broad spectrum anti-viral: Therapeutic with activity against more than one of the NIAID Category A, B and C viral threat agent AND including activity against at least one of the following viral pathogens: Ebola virus, Marburg virus, Variola major, Dengue virus, Chikungunya virus and human influenza virus.

Host-directed broad spectrum therapeutic: Therapeutic directed at a host response thereby reducing morbidity and mortality from exposure/infection and is effective against more than one of the NIAID Category A, B and C bacterial or viral threat AND including at least one of the following bacterial and viral pathogens: Bacillus, Ebola virus, Marburg virus, Variola major, Dengue virus, anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, Rickettsia prowazeki, Chikungunya virus and human influenza virus.

Further details are available under Solicitation Number: BAA-NIAID-DMID-NIH-AI-2014007.

From Our Partners
Tags: Animal ModelsAntimicrobialsAntiviralsBAANIAIDSynthetic Biology

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC